246 related articles for article (PubMed ID: 33313939)
1. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
[TBL] [Abstract][Full Text] [Related]
2. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
3. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
5. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin in combination with low-dose methotrexate in advanced-stage mycosis fungoides and Sézary syndrome.
Cieza-Díaz DE; Machan S; Prieto-Torres L; Requena L; Córdoba R
Dermatol Ther; 2021 May; 34(3):e14952. PubMed ID: 33724662
[No Abstract] [Full Text] [Related]
7. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
8. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
Gunter SJ; Kim EJ
J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
10. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
11. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
12. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
13. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
[TBL] [Abstract][Full Text] [Related]
15. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
Joshi TP; Duvic M
J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
[No Abstract] [Full Text] [Related]
16. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
17. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
18. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
19. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
Yamashita T; Abbade LP; Marques ME; Marques SA
An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
[TBL] [Abstract][Full Text] [Related]
20. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome.
Curry JL; Prieto VG; Jones DM; Vega F; Duvic M; Diwan AH
J Cutan Pathol; 2011 Mar; 38(3):295-7. PubMed ID: 19889052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
